The Athens, Ohio, company hopes to release kits related to Graves Disease and in 2010 its first HIV detection kit. It’s also preparing a kit to detect thyroid cancer. “We’re a very innovative company trying to be a very successful diagnostic company,” company President David Scholl said.

The approval completes a line of kits from Diagnostic HYBRIDS to detect other respiratory viruses. Respiratory kits make up the company’s top revenue stream.

The innovation determines the drug resistance and disease strength of the virus. Researchers think the approach can be used to better develop a vaccine.